Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Amikacin liposome inhalation suspension (Arikayce® )

To Patients

To Patients

Therapeutic Approach

Anti-Infective

Amikacin liposome inhalation suspension (Arikayce®) is an antibiotic to treat chronic lung infections caused by nontuberculous mycobacteria (NTM). 

Status

Arikayce® is FDA approved for the treatment of Mycobacterium aviumcomplex (MAC), which belongs to the nontuberculous mycobacteria (NTM) group.

Sponsor

The program was sponsored by Insmed Incorporated and partially funded by the Cystic Fibrosis Foundation. Multiple clinical trials were conducted within the Therapeutics Development Network.



Contact us about Amikacin liposome inhalation suspension (Arikayce® ) >